Report cover image

Onychomycosis Treatment Market Report by Disease Type (Distal Subungual Onychomycosis, Proximal Subungual Onychomycosis, White Superficial Onychomycosis, Candidal Onychomycosis, and Others), Treatment Type (Laser Therapy, Photodynamic Therapy, Drug Treatm

Publisher IMARC Services Pvt. Ltd.
Published Apr 01, 2025
Length 143 Pages
SKU # IMRC19910264

Description

The global onychomycosis treatment market size reached USD 3.6 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 5.4 Billion by 2033, exhibiting a growth rate (CAGR) of 4.5% during 2025-2033. The rising prevalence of this fungal infection among adults and millennials due to the increased exposure to public swimming pools and the use of tight, contaminated, or soiled clothes, shoes, socks, etc., is primarily driving the market.
  • nychomycosis is a fungal infection that occurs in the fingernails and toenails that can lead to discomfort, chronic pain and disfigurement. Proximal subungual, white superficial and distal subungual are some of the types of onychomycosis. It is a common nail infection in patients with athlete’s foot and is caused by various organisms, such as dermatophytes, yeasts and non-dermatophyte molds. Onychomycosis is characterized by symptoms, including distortion in the shape of nails, foul smell, whitish to yellow-brown discoloration and brittle, ragged and crumbly texture of the nails. It is usually diagnosed through potassium, oxygen and hydrogen (KOH) examination, culture and histopathological examinations of nail clippings and nail biopsies and is treated through laser therapy, drugs and photodynamic therapies.
  • nychomycosis Treatment Market Trends:
The increasing prevalence of chronic medical ailments, such as onychomycosis, human immunodeficiency virus (HIV), diabetes and peripheral artery disease (PAD), is one of the key factors driving the growth of the market. Moreover, the rising geriatric population, which is highly prone to circulatory disorders and weakened immune system, is providing a thrust to the market growth. Onychomycosis is also highly prevalent among millennials and adults due to the increased exposure to public swimming pools and utilization of tight, contaminated or soiled clothes, shoes and socks. Additionally, the development of water-soluble antifungal treatment solutions that can be administered orally is providing a thrust to the market growth. They aid in preventing secondary bacterial infections and prevent the growth of fungus. Other factors, including the widespread utilization of topical nail lacquers and ointments to maintain nail hygiene, along with the significant improvements in the healthcare infrastructure, are anticipated to drive the market toward growth.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with the onychomycosis treatment market forecast at the global, regional, and country levels for 2025-2033. Our report has categorized the market based on the disease type, treatment type, drug class, and distribution channel.

Breakup by Disease Type:
  • Distal Subungual Onychomycosis
  • Proximal Subungual Onychomycosis
  • White Superficial Onychomycosis
  • Candidal Onychomycosis
  • Others
Breakup by Treatment Type:
  • Laser Therapy
  • Photodynamic Therapy
  • Drug Treatment
Breakup by Drug Class:
  • Allylamine
  • Azole
  • Griseofulvin
  • Others
Breakup by Distribution Channel:
  • Hospitals and Clinics
  • Online Stores
  • Retail Pharmacies
  • Others
Breakup by Region:
  • North America
  • United States
  • Canada
  • Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa
Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Bausch Health Companies Inc., Cipla Limited, Dr. Reddy's Laboratories, Galderma SA, GlaxoSmithKline PLC, Kaken Pharmaceutical Co. Ltd, Lumenis Ltd, Moberg Pharma AB, Novartis AG, Pfizer Inc. and The OTC Lab B.V.

Key Questions Answered in This Report

1.What was the size of the global onychomycosis treatment market in 2024?

2.What is the expected growth rate of the global onychomycosis treatment market during 2025-2033?

3.What are the key factors driving the global onychomycosis treatment market?

4.What has been the impact of COVID-19 on the global onychomycosis treatment market?

5.What is the breakup of the global onychomycosis treatment market based on the disease type?

6.What is the breakup of the global onychomycosis treatment market based on the treatment type?

7.What is the breakup of the global onychomycosis treatment market based on the distribution channel?

8.What are the key regions in the global onychomycosis treatment market?

9.Who are the key players/companies in the global onychomycosis treatment market?

Table of Contents

143 Pages
1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Onychomycosis Treatment Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Disease Type
6.1 Distal Subungual Onychomycosis
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Proximal Subungual Onychomycosis
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 White Superficial Onychomycosis
6.3.1 Market Trends
6.3.2 Market Forecast
6.4 Candidal Onychomycosis
6.4.1 Market Trends
6.4.2 Market Forecast
6.5 Others
6.5.1 Market Trends
6.5.2 Market Forecast
7 Market Breakup by Treatment Type
7.1 Laser Therapy
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Photodynamic Therapy
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Drug Treatment
7.3.1 Market Trends
7.3.2 Market Forecast
8 Market Breakup by Drug Class
8.1 Allylamine
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Azole
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Griseofulvin
8.3.1 Market Trends
8.3.2 Market Forecast
8.4 Others
8.4.1 Market Trends
8.4.2 Market Forecast
9 Market Breakup by Distribution Channel
9.1 Hospitals and Clinics
9.1.1 Market Trends
9.1.2 Market Forecast
9.2 Online Stores
9.2.1 Market Trends
9.2.2 Market Forecast
9.3 Retail Pharmacies
9.3.1 Market Trends
9.3.2 Market Forecast
9.4 Others
9.4.1 Market Trends
9.4.2 Market Forecast
10 Market Breakup by Region
10.1 North America
10.1.1 United States
10.1.1.1 Market Trends
10.1.1.2 Market Forecast
10.1.2 Canada
10.1.2.1 Market Trends
10.1.2.2 Market Forecast
10.2 Asia-Pacific
10.2.1 China
10.2.1.1 Market Trends
10.2.1.2 Market Forecast
10.2.2 Japan
10.2.2.1 Market Trends
10.2.2.2 Market Forecast
10.2.3 India
10.2.3.1 Market Trends
10.2.3.2 Market Forecast
10.2.4 South Korea
10.2.4.1 Market Trends
10.2.4.2 Market Forecast
10.2.5 Australia
10.2.5.1 Market Trends
10.2.5.2 Market Forecast
10.2.6 Indonesia
10.2.6.1 Market Trends
10.2.6.2 Market Forecast
10.2.7 Others
10.2.7.1 Market Trends
10.2.7.2 Market Forecast
10.3 Europe
10.3.1 Germany
10.3.1.1 Market Trends
10.3.1.2 Market Forecast
10.3.2 France
10.3.2.1 Market Trends
10.3.2.2 Market Forecast
10.3.3 United Kingdom
10.3.3.1 Market Trends
10.3.3.2 Market Forecast
10.3.4 Italy
10.3.4.1 Market Trends
10.3.4.2 Market Forecast
10.3.5 Spain
10.3.5.1 Market Trends
10.3.5.2 Market Forecast
10.3.6 Russia
10.3.6.1 Market Trends
10.3.6.2 Market Forecast
10.3.7 Others
10.3.7.1 Market Trends
10.3.7.2 Market Forecast
10.4 Latin America
10.4.1 Brazil
10.4.1.1 Market Trends
10.4.1.2 Market Forecast
10.4.2 Mexico
10.4.2.1 Market Trends
10.4.2.2 Market Forecast
10.4.3 Others
10.4.3.1 Market Trends
10.4.3.2 Market Forecast
10.5 Middle East and Africa
10.5.1 Market Trends
10.5.2 Market Breakup by Country
10.5.3 Market Forecast
11 SWOT Analysis
11.1 Overview
11.2 Strengths
11.3 Weaknesses
11.4 Opportunities
11.5 Threats
12 Value Chain Analysis
13 Porters Five Forces Analysis
13.1 Overview
13.2 Bargaining Power of Buyers
13.3 Bargaining Power of Suppliers
13.4 Degree of Competition
13.5 Threat of New Entrants
13.6 Threat of Substitutes
14 Price Analysis
15 Competitive Landscape
15.1 Market Structure
15.2 Key Players
15.3 Profiles of Key Players
15.3.1 Bausch Health Companies Inc.
15.3.1.1 Company Overview
15.3.1.2 Product Portfolio
15.3.1.3 Financials
15.3.1.4 SWOT Analysis
15.3.2 Cipla Limited
15.3.2.1 Company Overview
15.3.2.2 Product Portfolio
15.3.3 Dr. Reddy's Laboratories
15.3.3.1 Company Overview
15.3.3.2 Product Portfolio
15.3.3.3 Financials
15.3.3.4 SWOT Analysis
15.3.4 Galderma SA
15.3.4.1 Company Overview
15.3.4.2 Product Portfolio
15.3.5 GlaxoSmithKline PLC
15.3.5.1 Company Overview
15.3.5.2 Product Portfolio
15.3.5.3 Financials
15.3.5.4 SWOT Analysis
15.3.6 Kaken Pharmaceutical Co. Ltd
15.3.6.1 Company Overview
15.3.6.2 Product Portfolio
15.3.6.3 Financials
15.3.7 Lumenis Ltd
15.3.7.1 Company Overview
15.3.7.2 Product Portfolio
15.3.7.3 SWOT Analysis
15.3.8 Moberg Pharma AB
15.3.8.1 Company Overview
15.3.8.2 Product Portfolio
15.3.8.3 Financials
15.3.9 Novartis AG
15.3.9.1 Company Overview
15.3.9.2 Product Portfolio
15.3.9.3 Financials
15.3.9.4 SWOT Analysis
15.3.10 Pfizer Inc.
15.3.10.1 Company Overview
15.3.10.2 Product Portfolio
15.3.10.3 Financials
15.3.10.4 SWOT Analysis
15.3.11 The OTC Lab B.V.
15.3.11.1 Company Overview
15.3.11.2 Product Portfolio

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us